Result:Steady· Market: Up#Base effect
| Metric | Value (₹ Cr) | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 1.24 | 29.0% | 20.8% |
| Total Income | 1.36 | 29.1% | 17.0% |
| Expenditure | 1.22 | 28.2% | 17.3% |
| PBT | 2.90 | 1244.4% | 1705.3% |
| Net Profit | 2.40 | 1302.6% | 1914.4% |
| OPM | 100.00% | 94.80pp | 91.30pp |
| NPM | 100.00% | 91.09pp | 92.74pp |
| EPS | 9.53 | 1301.5% | 1664.8% |
Revenue fell 20.8% YoY (core metric for pharma) even though PAT jumped off a negligible prior-year base of ~₹0.12 Cr, so the profit surge is a base effect rather than genuine core growth.
Informational and educational content only. Not investment advice.